← Back to latest
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Cantor Global Healthcare Conference 2026 DateTime: Fireside chat on Wednesday, September 9, 2026 at 3:55 p.m. ET Citi’s 2026 ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will part... [1712 chars]
News providers only return a preview of the article body. Continue reading the full story at the original source.
Investing News Network →
